Verrica Pharmaceuticals Inc. (VRCA) revealed that the U.S. Food and Drug Administration (FDA) extended the review period by three months for its New Drug Application (NDA) of VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious viral skin disease. The Prescription Drug User Fee Act (PDUFA) goal date has also been postponed by three months to September 23, 2021. (See Verrica Pharmaceuticals stock analysis on TipRanks) The extension has provided the agency some additional time to review the information submitted by Verrica, including its training program and distribution model, in response to comments from the agency regarding the company’s human factors study, the company said.
https://www.tipranks.com/news/fda-extends-review-period-for-verrica-pharmaceuticals-vp-102-drug-application
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Verrica Parmaceuticals Charts.
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Verrica Parmaceuticals Charts.